Clinical Trials Browser

Phase 2 × 1 year × Clear all

NCT02314169 2026-04-22

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

Phase 2 Active not recruiting

143 enrolled 16 charts

Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT02433795 2026-04-22

Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)

Phase 2 Completed

27 enrolled 12 charts

Lymphoma, B-Cell, Marginal Zone

NCT02667574 2026-04-22

VISMONEO

Phase 2 Completed

Carcinoma, Basal Cell

NCT02874430 2026-04-22

Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer

Phase 2 Terminated

29 enrolled 11 charts

Breast Neoplasms

NCT02974647 2026-04-22

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Phase 2 Recruiting

Lymphoma, Recurrence

NCT03138720 2026-04-22

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

Phase 2 Completed

40 enrolled 22 charts

Gastrointestinal

Resectable Pancreatic Cancer

NCT03181867 2026-04-22

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03210714 2026-04-22

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Phase 2 Active not recruiting

20 enrolled 10 charts

CNSGastrointestinalGenitourinaryLymphoidMyeloid

Familial ependymoma, Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03436654 2026-04-22

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03481114 2026-04-22

REPAINT

Phase 2 Completed

55 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT03625323 2026-04-22

TACTI-002

Phase 2 Completed

187 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck

NCT03736889 2026-04-22

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

Phase 2 Recruiting

Other solid neoplasm

MSI-H/dMMR Solid Tumors

NCT03866382 2026-04-22

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Phase 2 Recruiting

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT03981146 2026-04-22

ANICCA

Phase 2 Completed

35 enrolled 15 charts

Gastrointestinal

Colorectal Neoplasms

NCT04049331 2026-04-22

Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone

Phase 2 Active not recruiting

Eunuchism, Hypogonadism, Fatigue Syndrome, Chronic

NCT04080804 2026-04-22

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04082520 2026-04-22

Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

Phase 2 Recruiting

Meningioma

NCT04123366 2026-04-22

MK-7339-007

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT04452955 2026-04-22

A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors

Phase 2 Active not recruiting

Neoplasms

NCT04530552 2026-04-22

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

Phase 2 Active not recruiting

34 enrolled 11 charts

Prostatic Neoplasms

NCT04665739 2026-04-22

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Phase 2 Recruiting

Advanced Lung Neuroendocrine Tumor

NCT04701307 2026-04-22

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

Phase 2 Active not recruiting

EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT04837820 2026-04-22

The Effect of Acupuncture on Cancer-Related Cognitive Difficulties

Phase 2 Active not recruiting

Breast Neoplasms

NCT04858334 2026-04-22

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Phase 2 Recruiting

Gastrointestinal

Pancreatic Acinar Cell Carcinoma

NCT04891289 2026-04-22

Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

Phase 2 Recruiting

Gastrointestinal

Cholangiocarcinoma

NCT04917809 2026-04-22

A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

Phase 2 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05198830 2026-04-22

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Phase 2 Recruiting

Adenocarcinoma of Lung, Lung Neoplasms

NCT05507541 2026-04-22

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Active not recruiting

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05554328 2026-04-22

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05554393 2026-04-22

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05583708 2026-04-22

iPRRT

Phase 2 Recruiting

Carcinoma, Merkel Cell

NCT05596409 2026-04-22

ELCIN

Phase 2 Active not recruiting

Breast Neoplasms

NCT05638295 2026-04-22

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT05655949 2026-04-22

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Phase 2 Recruiting

Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

NCT05843253 2026-04-22

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Phase 2 Recruiting

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

NCT05972135 2026-04-22

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Phase 2 Recruiting

Cytokine Release Syndrome, Multiple Myeloma

NCT06027268 2026-04-22

ToPCourT

Phase 2 Active not recruiting

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06126276 2026-04-22

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

Phase 2 Recruiting

Other solid neoplasm

Malignant Female Reproductive System Neoplasm

NCT06180356 2026-04-22

ANALLISA

Phase 2 Recruiting

Ovarian Neoplasms

NCT06406465 2026-04-22

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Phase 2 Recruiting

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT06423326 2026-04-22

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Phase 2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06514794 2026-04-22

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06528691 2026-04-22

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

Phase 2 Recruiting

Glioma, Central Nervous System Neoplasms

NCT06599762 2026-04-22

MYELO-CAN:TXA

Phase 2 Recruiting

Classical hematologyMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Thrombocytopenia, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT06637501 2026-04-22

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06649812 2026-04-22

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06672146 2026-04-22

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06769152 2026-04-22

A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors

Phase 2 Recruiting

Uterine Cervical Neoplasms, Ovarian Neoplasms

NCT06773910 2026-04-22

TIGOS-LS

Phase 2 Recruiting

Limited Stage Small Cell Lung Cancer

NCT06805305 2026-04-22

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

Phase 2 Recruiting

Glioblastoma